<DOC>
	<DOCNO>NCT00242294</DOCNO>
	<brief_summary>The aim study investigate effect roflumilast ( APTA-2217 ) lung function patient chronic obstructive pulmonary disease ( COPD ) . Roflumilast administer orally daily . The study duration consist baseline period ( 4 week ) treatment period ( 24 week ) . The study provide data safety , tolerability , effectiveness roflumilast .</brief_summary>
	<brief_title>Efficacy Safety Roflumilast Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease ( APTA-2217-06 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main inclusion criterion : Patients chronic obstructive pulmonary disease Current smoker exsmoker 30 80 % predict FEV1 inhalation short act beta stimulant Main exclusion criterion : Patients poorly control COPD Patients need longterm oxygen therapy Patients concurrent respiratory disease asthma , diffuse panbronchiolitis , congenital sinobronchial syndrome , bronchiolitis obliterans , bronchiectasis , active tuberculosis , pneumoconiosis , pulmonary lymph vascular myoma , consider affect evaluation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Phosphodiesterase 4 inhibitor</keyword>
	<keyword>Roflumilast</keyword>
</DOC>